米国の前立腺がんバイオマーカー市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、セグメント予測、2025年～2033年

市場規模と動向

米国の前立腺がんバイオマーカー市場規模は2024年に17億米ドルと推定され、2025～2033年にかけてCAGR 14.74％で成長すると予測されています。

市場成長の原動力は、前立腺がんの有病率の上昇、早期発見に対する意識、精密診断の採用です。リキッドバイオプシー、ゲノミクス、非侵襲的バイオマーカー技術の進歩は、スクリーニング精度と患者の層別化を強化しています。さらに、個別化治療計画に対する需要の高まりと、PSA、PCA3、遺伝子発現パネル（Decipher、Oncotype DXなど）などの診断検査に対する有利な償還制度の枠組みが、市場の成長をさらに加速させています。戦略的提携や継続的な研究開発投資も、バイオマーカーのパイプラインと商業的利用可能性を拡大しています。

前立腺がんは、米国で男性が罹患する最も罹患率の高い悪性腫瘍のひとつです。米国がん協会によると、男性の8人に1人が生涯のうちにこの病気と診断されます。2022年だけでも、推定268,500人の新規患者が報告され、約34,500人が死亡しており、米国人男性のがん死亡原因の第2位となっています。現在、米国では310万人以上の男性が前立腺がんと共に生きています。このような膨大な患者数に加え、良性・悪性を区別する特異性に欠けるPSA検査などの従来型診断法には限界があるため、早期発見、リスク層別化、治療の個別化を可能にする新規バイオマーカーに対する強い需要が生じています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の前立腺がんバイオマーカー市場の変数、動向、範囲

• 米国の前立腺がんバイオマーカー市場の系統展望
  • 親市場の展望
• 浸透と成長の展望マッピング
• パイプライン分析
  • スクリーニングと早期発見
  • 診断とリスク層別化
  • 予後と治療のモニタリング
  • コンパニオン診断
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 前立腺がんバイオマーカー：市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 米国の前立腺がんバイオマーカー市場：セグメント分析、タイプ別、2021～2033年

• 米国の前立腺がんバイオマーカー市場：タイプ変動分析

第5章 米国の前立腺がんバイオマーカー市場：セグメント分析、用途別、2021～2033年

• 米国の前立腺がんバイオマーカー市場：用途変動分析

第6章 米国の前立腺がんバイオマーカー市場：セグメント分析、最終用途別、2021～2033年

• 米国の前立腺がんバイオマーカー市場：最終用途変動分析

第7章 米国の前立腺がんバイオマーカー市場：競合分析

• 企業分類
• 戦略マッピング
  • 新製品発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 2022年の企業市場シェア分析
• 企業プロファイル
  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • Bio-techne
  • Exodx
  • Opko Health, Inc.
  • Mdxhealth
  • Veracyte, Inc.
  • Beckman Coulter, Inc.
  • Nucleix
  • Diacarta

List of Tables

• Table 1 List of Abbreviations
• Table 2 U.S. prostate cancer biomarkers market, by application, 2021 - 2033 (USD Million)
• Table 3 U.S. prostate cancer biomarkers market, by type, 2021 - 2033 (USD Million)
• Table 4 U.S. prostate cancer biomarkers market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Prostate Cancer Biomarkers market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (Type and application)
• Fig. 11 Segment snapshot (End use)
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Biomarkers market value, 2024 (USD Million)
• Fig. 14 Prostate Cancer Biomarkers market dynamics
• Fig. 15 Prevalence of Screening and Early Detection by age group, 2024
• Fig. 16 Prostate Cancer Biomarkers market: PORTER's analysis
• Fig. 17 Prostate Cancer Biomarkers market: PESTLE analysis
• Fig. 18 Prostate Cancer Biomarkers market: Type outlook and key takeaways
• Fig. 19 Prostate Cancer Biomarkers market: Type movement analysis
• Fig. 20 Genetic Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 21 Protein Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 22 Cell-based Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 23 Metabolomic Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 24 Prostate Cancer Biomarkers market: Application outlook and key takeaways
• Fig. 25 Prostate Cancer Biomarkers market: Application movement analysis
• Fig. 26 Screening and Early Detection market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 27 Diagnosis and Risk Stratification market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 28 Prognosis and Treatment Monitoring market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 29 Companion Diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 30 Prostate Cancer Biomarkers market: End use outlook and key takeaways
• Fig. 31 Prostate Cancer Biomarkers market: End use movement analysis
• Fig. 32 Hospitals and Diagnostic Laboratories market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 33 Academic and Research Institutes market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 34 Biopharmaceutical Companies market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 35 Key company categorization
• Fig. 36 Company market positioning
• Fig. 37 Company market share analysis, 2024
• Fig. 38 Strategic framework

Market Size & Trends:

The U.S. prostate cancer biomarkers market size was estimated at USD 1.7 billion in 2024 and is expected to grow at a CAGR of 14.74% from 2025 to 2033. The market growth is driven by the rising prevalence of prostate cancer, awareness around early detection, and adoption of precision diagnostics. Advancements in liquid biopsy, genomics, and non-invasive biomarker technologies are enhancing screening accuracy and patient stratification. Additionally, the rising demand for personalized treatment planning, along with favorable reimbursement frameworks for diagnostic tests such as PSA, PCA3, and gene-expression panels (e.g., Decipher, Oncotype DX), is further accelerating market growth. Strategic collaborations and continuous R&D investment are also expanding the biomarker pipeline and commercial availability.

Prostate cancer is one of the most prevalent malignancies affecting men in the United States. According to the American Cancer Society, 1 in 8 men will be diagnosed with the disease in their lifetime. In 2022 alone, an estimated 268,500 new cases were reported, with approximately 34,500 deaths, making it the second leading cause of cancer death among American men. Today, over 3.1 million men in the U.S. are living with prostate cancer. This substantial patient population, along with limitations in traditional diagnostics such as PSA testing, which lacks specificity to distinguish between benign and malignant conditions, has created strong demand for novel biomarkers that can enable earlier detection, improved risk stratification, and treatment personalization.

U.S. Prostate Cancer Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-markets from 2021 to 2033. For this study, Grand View Research has segmented the U.S. prostate cancer biomarkers market report based on type, application, and end-use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic Biomarkers
  • Protein Biomarkers
  • Cell-based Biomarkers
  • Metabolomic Biomarkers
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Screening and Early Detection
  • Diagnosis and Risk Stratification
  • Prognosis and Treatment Monitoring
  • Companion Diagnostics
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Institutes
  • Biopharmaceutical Companies

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definition
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Type Segment
    • 1.1.1.3 End USE Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 GVR's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Type Snapshot
• 2.3 End USE Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. Prostate Cancer Biomarkers Market Variables, Trends, And Scope

• 3.1 U.S. Prostate Cancer Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Pipeline Analysis
  • 3.3.1 Screening And Early Detection
  • 3.3.2 Diagnosis And Risk Stratification
  • 3.3.3 Prognosis And Treatment Monitoring
  • 3.3.4 Companion Diagnostics
• 3.4 Market Dynamics
  • 3.4.1 Market Driver Analysis
    • 3.4.1.1 Rising Prevalence Of Prostate Cancer
    • 3.4.1.2 Advancements In Genomic And Proteomic Technologies
    • 3.4.1.3 Supportive Government And Research Initiatives
  • 3.4.2 Market Restraint Analysis
    • 3.4.2.1 High Cost Of Biomarker-based Tests
    • 3.4.2.2 Uneven Access To Advanced Diagnostic Infrastructure
• 3.5 Prostate Cancer Biomarkers: Market Analysis Tools
  • 3.5.1 Industry Analysis - Porter's
  • 3.5.2 Pestle Analysis

Chapter 4 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Type, 2021 - 2033 (USD Million)

• 4.1 U.S. Prostate Cancer Biomarkers Market: Type Movement Analysis
  • 4.1.1 Genetic Biomarkers
    • 4.1.1.1 Genetic Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.2 Protein Biomarkers
    • 4.1.2.1 Protein Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.3 Cell-based Biomarkers
    • 4.1.3.1 Cell-based Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.5 Metabolomic Biomarkers
    • 4.1.5.1 Metabolomic Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)

Chapter 5 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Application, 2021 - 2033 (USD Million)

• 5.1 U.S. Prostate Cancer Biomarkers Market: Application Movement Analysis
  • 5.1.1 Screening And Early Detection
    • 5.1.1.1 Screening And Early Detection Market, 2021 - 2033 (USD Million)
  • 5.1.2 Diagnosis And Risk Stratification
  • 515.2.1 Diagnosis And Risk Stratification Market, 2021 - 2033 (USD Million)
  • 5.1.3 Prognosis And Treatment Monitoring
  • 51.3.1 Prognosis And Treatment Monitoring Market, 2021 - 2033 (USD Million)
  • 5.1.4 Companion Diagnostics
    • 5.1.4.1 Companion Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 6 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By End USE, 2021 - 2033 (USD Million)

• 6.1 U.S. Prostate Cancer Biomarkers Market: End USE Movement Analysis
  • 6.1.1 Hospitals And Diagnostic Laboratories
    • 6.1.1.1 Hospitals And Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
  • 6.1.2 Academic And Research Institutes
    • 6.1.2.1 Academic And Research Institutes Market, 2021 - 2033 (USD Million)
  • 6.1.3 Biopharmaceutical Companies
    • 6.1.3.1 Biopharmaceutical Companies Market, 2021 - 2033 (USD Million)

Chapter 7 U.S. Prostate Cancer Biomarkers Market: Competitive Analysis

• 7.1 Company Categorization
• 7.2 Strategy Mapping
  • 7.2.1 New Product Launch
  • 7.2.2 Partnerships
  • 7.2.3 Acquisition
  • 7.2.4 Collaboration
  • 7.2.5 Funding
• 7.3 Company Market Share Analysis, 2022
• 7.4 Company Profiles
  • 7.4.1 Exact Sciences Corporation
    • 7.4.1.1 Company Overview
    • 7.4.1.2 Financial Performance
    • 7.4.1.3 Product Benchmarking
    • 7.4.1.4 Strategic Initiatives
  • 7.4.2 Myriad Genetics, Inc.
    • 7.4.2.1 Company Overview
    • 7.4.2.2 Financial Performance
    • 7.4.2.3 Product Benchmarking
    • 7.4.2.4 Strategic Initiatives
  • 7.4.3 Bio-techne
    • 7.4.3.1 Company Overview
    • 7.4.3.2 Financial Performance
    • 7.4.3.3 Product Benchmarking
    • 7.4.3.4 Strategic Initiatives
  • 7.4.4 Exodx
    • 7.4.4.1 Company Overview
    • 7.4.4.2 Product Benchmarking
  • 7.4.5 Opko Health, Inc.
    • 7.4.5.1 Company Overview
    • 7.4.5.2 Product Benchmarking
    • 7.4.5.3 Strategic Initiatives
  • 7.4.6 Mdxhealth
    • 7.4.6.1 Company Overview
    • 7.4.6.2 Financial Performance
    • 7.4.6.3 Product Benchmarking
    • 7.4.6.4 Strategic Initiatives
  • 7.4.7 Veracyte, Inc.
    • 7.4.7.1 Company Overview
    • 7.4.7.2 Financial Performance
    • 7.4.7.3 Product Benchmarking
    • 7.4.7.4 Strategic Initiatives
  • 7.4.8 Beckman Coulter, Inc.
    • 7.4.8.1 Company Overview
    • 7.4.8.2 Product Benchmarking
  • 7.4.9 Nucleix
    • 7.4.9.1 Company Overview
    • 7.4.9.2 Financial Performance
    • 7.4.9.3 Product Benchmarking
    • 7.4.9.4 Strategic Initiatives
  • 7.4.10 Diacarta
    • 7.4.10.1 Company Overview
    • 7.4.10.2 Product Benchmarking
    • 7.4.10.3 Strategic Initiatives